Cipla, Amgen settle case involving generic cinacalcet hydrochloride tablets

20 Jul 2020 Evaluate
Cipla has reached a settlement with Amgen Inc on pending litigation involving generic cinacalcet hydrochloride tablets, used in the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease. A formal stipulation of dismissal has been filed with the court and is awaiting signature by the presiding Judge. The resolution entitles the company and its affiliates to continue importing, marketing, and selling its generic cinacalcet hydrochloride tablets in the United States.

Cipla's cinacalcet hydrochloride tablets, in the strengths of 30mg, 60mg, and 90mg, are generic versions of Sensipar, a branded drug marketed by Amgen Inc. Cinacalcet tablets are indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis, for the treatment of hypercalcemia in adult patients with Parathyroid Carcinoma, and for treatment of severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1517.20 5.10 (0.34%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×